Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence

Jason M. D'Antonio, Changqing Ma, Federico A. Monzon, Beth Pflug

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

BACKGROUND. Following androgen ablation therapy, the majority of prostate cancer patients develop treatment resistance with a median time of 18-24 months to disease progression. METHODS. To identify molecular targets that promote prostate cancer cell survival and contribute to androgen independence, we evaluated changes in LNCaP cell gene expression during 12 months of androgen deprivation. At time points reflecting critical growth and phenotypic changes, we performed Affymetrix expression array analysis to examine the effects of androgen deprivation during the acute response, during the period of apparent quiescence, and following the emergence of a highly proliferative, androgen-independent prostate cancer cell phenotype (LNCaP-AI). RESULTS. We discovered alterations in gene expression for molecules associated with promoting prostate cancer cell growth and survival, and regulating cell cycle progression and apoptosis. Additionally, expression of AR co-regulators, adrenal androgen metabolizing enzymes, and markers of neuroendocrine disease were significantly altered. CONCLUSIONS. These findings contribute greatly to our understanding of androgen-independent prostate cancer. The value of this longitudinal approach lies in the ability to examine gene expression changes throughout the adaptive response to androgen deprivation; it provides a more dynamic illustration of genes which contribute to disease progression in addition to specific genes which constitute an androgen-independent phenotype.

Original languageEnglish (US)
Pages (from-to)698-714
Number of pages17
JournalProstate
Volume68
Issue number7
DOIs
StatePublished - May 15 2008
Externally publishedYes

Fingerprint

Androgens
Prostatic Neoplasms
Gene Expression
Disease Progression
Cell Survival
Phenotype
Growth
Genes
Cell Cycle
Apoptosis
Enzymes
Therapeutics

Keywords

  • Androgen ablation
  • Androgen-independent prostate cancer
  • Gene expression array
  • Survival

ASJC Scopus subject areas

  • Urology

Cite this

Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence. / D'Antonio, Jason M.; Ma, Changqing; Monzon, Federico A.; Pflug, Beth.

In: Prostate, Vol. 68, No. 7, 15.05.2008, p. 698-714.

Research output: Contribution to journalArticle

D'Antonio, Jason M. ; Ma, Changqing ; Monzon, Federico A. ; Pflug, Beth. / Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence. In: Prostate. 2008 ; Vol. 68, No. 7. pp. 698-714.
@article{c9ae7313448b49988f4b6aee7ed4e4be,
title = "Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence",
abstract = "BACKGROUND. Following androgen ablation therapy, the majority of prostate cancer patients develop treatment resistance with a median time of 18-24 months to disease progression. METHODS. To identify molecular targets that promote prostate cancer cell survival and contribute to androgen independence, we evaluated changes in LNCaP cell gene expression during 12 months of androgen deprivation. At time points reflecting critical growth and phenotypic changes, we performed Affymetrix expression array analysis to examine the effects of androgen deprivation during the acute response, during the period of apparent quiescence, and following the emergence of a highly proliferative, androgen-independent prostate cancer cell phenotype (LNCaP-AI). RESULTS. We discovered alterations in gene expression for molecules associated with promoting prostate cancer cell growth and survival, and regulating cell cycle progression and apoptosis. Additionally, expression of AR co-regulators, adrenal androgen metabolizing enzymes, and markers of neuroendocrine disease were significantly altered. CONCLUSIONS. These findings contribute greatly to our understanding of androgen-independent prostate cancer. The value of this longitudinal approach lies in the ability to examine gene expression changes throughout the adaptive response to androgen deprivation; it provides a more dynamic illustration of genes which contribute to disease progression in addition to specific genes which constitute an androgen-independent phenotype.",
keywords = "Androgen ablation, Androgen-independent prostate cancer, Gene expression array, Survival",
author = "D'Antonio, {Jason M.} and Changqing Ma and Monzon, {Federico A.} and Beth Pflug",
year = "2008",
month = "5",
day = "15",
doi = "10.1002/pros.20677",
language = "English (US)",
volume = "68",
pages = "698--714",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence

AU - D'Antonio, Jason M.

AU - Ma, Changqing

AU - Monzon, Federico A.

AU - Pflug, Beth

PY - 2008/5/15

Y1 - 2008/5/15

N2 - BACKGROUND. Following androgen ablation therapy, the majority of prostate cancer patients develop treatment resistance with a median time of 18-24 months to disease progression. METHODS. To identify molecular targets that promote prostate cancer cell survival and contribute to androgen independence, we evaluated changes in LNCaP cell gene expression during 12 months of androgen deprivation. At time points reflecting critical growth and phenotypic changes, we performed Affymetrix expression array analysis to examine the effects of androgen deprivation during the acute response, during the period of apparent quiescence, and following the emergence of a highly proliferative, androgen-independent prostate cancer cell phenotype (LNCaP-AI). RESULTS. We discovered alterations in gene expression for molecules associated with promoting prostate cancer cell growth and survival, and regulating cell cycle progression and apoptosis. Additionally, expression of AR co-regulators, adrenal androgen metabolizing enzymes, and markers of neuroendocrine disease were significantly altered. CONCLUSIONS. These findings contribute greatly to our understanding of androgen-independent prostate cancer. The value of this longitudinal approach lies in the ability to examine gene expression changes throughout the adaptive response to androgen deprivation; it provides a more dynamic illustration of genes which contribute to disease progression in addition to specific genes which constitute an androgen-independent phenotype.

AB - BACKGROUND. Following androgen ablation therapy, the majority of prostate cancer patients develop treatment resistance with a median time of 18-24 months to disease progression. METHODS. To identify molecular targets that promote prostate cancer cell survival and contribute to androgen independence, we evaluated changes in LNCaP cell gene expression during 12 months of androgen deprivation. At time points reflecting critical growth and phenotypic changes, we performed Affymetrix expression array analysis to examine the effects of androgen deprivation during the acute response, during the period of apparent quiescence, and following the emergence of a highly proliferative, androgen-independent prostate cancer cell phenotype (LNCaP-AI). RESULTS. We discovered alterations in gene expression for molecules associated with promoting prostate cancer cell growth and survival, and regulating cell cycle progression and apoptosis. Additionally, expression of AR co-regulators, adrenal androgen metabolizing enzymes, and markers of neuroendocrine disease were significantly altered. CONCLUSIONS. These findings contribute greatly to our understanding of androgen-independent prostate cancer. The value of this longitudinal approach lies in the ability to examine gene expression changes throughout the adaptive response to androgen deprivation; it provides a more dynamic illustration of genes which contribute to disease progression in addition to specific genes which constitute an androgen-independent phenotype.

KW - Androgen ablation

KW - Androgen-independent prostate cancer

KW - Gene expression array

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=43049131149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049131149&partnerID=8YFLogxK

U2 - 10.1002/pros.20677

DO - 10.1002/pros.20677

M3 - Article

C2 - 18302219

AN - SCOPUS:43049131149

VL - 68

SP - 698

EP - 714

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 7

ER -